Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Accounts Payable & Accrued Expense : $3.97 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Accounts Payable & Accrued Expense?

Infant Bacterial Therapeutics AB's quarterly accounts payable & accrued expense increased from Sep. 2023 ($2.30 Mil) to Dec. 2023 ($2.93 Mil) and increased from Dec. 2023 ($2.93 Mil) to Mar. 2024 ($3.97 Mil).

Infant Bacterial Therapeutics AB's annual accounts payable & accrued expense increased from Dec. 2021 ($0.53 Mil) to Dec. 2022 ($0.84 Mil) and increased from Dec. 2022 ($0.84 Mil) to Dec. 2023 ($2.93 Mil).

Infant Bacterial Therapeutics AB Accounts Payable & Accrued Expense Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Accounts Payable & Accrued Expense Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

0.10

0.15

0.53

0.84

2.93

Infant Bacterial Therapeutics AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															0.68	1.70	2.30	2.93	3.97

Infant Bacterial Therapeutics AB Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (GREY:IFTBF) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

IBT B:Sweden 9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevents or treats rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Headlines

No Headlines